Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

VesiCURE Says Stem Cell Derived Extracellular Vesicles Effective in UC

publication date: Apr 10, 2024

Suzhou VesiCURE Therapeutics reports its mesenchymal stem cell-derived extracellular vesicles showed efficacy in a mouse model of ulcerative colitis. Mesenchymal stem cells (MSCs) are pluripotent stem cells that can modulate immune cells in their microenvironment by secreting growth factors, chemokines and extracellular vesicles (EVs). EVs have been shown to repair damaged intestinal epithelial barriers and recover GI function in intestinal bowel disease. VesiCURE recently published an article that reviewed the use of its MSC-EV technology in an animal UC test. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital